| Literature DB >> 19072656 |
Stefania Butini1, Sandra Gemma, Giuseppe Campiani, Silvia Franceschini, Francesco Trotta, Marianna Borriello, Nicoletta Ceres, Sindu Ros, Salvatore Sanna Coccone, Matteo Bernetti, Meri De Angelis, Margherita Brindisi, Vito Nacci, Isabella Fiorini, Ettore Novellino, Alfredo Cagnotto, Tiziana Mennini, Karin Sandager-Nielsen, Jesper Tobias Andreasen, Jorgen Scheel-Kruger, Jens D Mikkelsen, Caterina Fattorusso.
Abstract
Dopamine D(3) antagonism combined with serotonin 5-HT(1A) and 5-HT(2A) receptor occupancy may represent a novel paradigm for developing innovative antipsychotics. The unique pharmacological features of 5i are a high affinity for dopamine D(3), serotonin 5-HT(1A) and 5-HT(2A) receptors, together with a low affinity for dopamine D(2) receptors (to minimize extrapyramidal side effects), serotonin 5-HT(2C) receptors (to reduce the risk of obesity under chronic treatment), and for hERG channels (to reduce incidence of torsade des pointes). Pharmacological and biochemical data, including specific c-fos expression in mesocorticolimbic areas, confirmed an atypical antipsychotic profile of 5i in vivo, characterized by the absence of catalepsy at antipsychotic dose.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19072656 DOI： 10.1021/jm800689g
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446